Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Paradigm Biocapital Advisors LP

Q3 2024 · 13F-HR

Paradigm Biocapital Advisors LPholdings as filed

Filed 2024-11-14 · accession 0001855655-24-000014

$2.96B
Reported value
33
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
670703107NUVLNUVALENT INC$511.5M17.3%5,000,000CommonSOLE
03940C100ACLXGBXARCELLX INC$334.0M11.3%4,000,000CommonSOLE
04016X101ARGXARGENX SE$260.4M8.81%480,374CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$241.0M8.15%5,314,089CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$128.6M4.35%2,516,686CommonSOLE
N5749R1002GHMERUS N V$122.6M4.15%2,454,917CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$109.1M3.69%2,400,574CommonSOLE
50127T109KURAKURA ONCOLOGY INC$84.6M2.86%4,331,321CommonSOLE
87650L103TARSTARSUS PHARMACEUTICALS INC$80.3M2.72%2,440,445CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$74.4M2.52%2,789,172CommonSOLE
254604101IRONDISC MEDICINE INC$73.6M2.49%1,497,720CommonSOLE
92243G108PCVXVAXCYTE INC$71.7M2.43%627,732CommonSOLE
03940C100ACLXGBXARCELLX INC$66.8M2.26%800,000CALLSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$65.9M2.23%2,895,689CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$65.7M2.22%5,503,600CommonSOLE
04335A105ARVNARVINAS INC$57.6M1.95%2,339,961CommonSOLE
984241109YMABUSDY-MABS THERAPEUTICS INC$53.7M1.82%4,086,346CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$49.8M1.68%4,609,762CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$48.5M1.64%1,096,851CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$47.0M1.59%931,480CommonSOLE
07725L102ONCBEIGENE LTD$45.0M1.52%200,336CommonSOLE
N44445109IMTXIMMATICS N.V$44.6M1.51%3,904,862CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$41.2M1.39%701,817CommonSOLE
45258J102IMVTIMMUNOVANT INC$38.9M1.31%1,362,827CommonSOLE
230031106CGEMCULLINAN THERAPEUTICS INC$38.9M1.31%2,321,013CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$37.3M1.26%1,267,581CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$34.8M1.18%3,104,486CommonSOLE
92243G108PCVXVAXCYTE INC$31.6M1.07%276,800CALLSOLE
492327101KROSKEROS THERAPEUTICS INC$30.5M1.03%525,037CommonSOLE
29479A108ERASERASCA INC$29.1M0.99%10,668,141CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$17.6M0.60%719,660CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$12.3M0.42%919,692CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$7.3M0.25%1,160,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.